A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Public ClinicalTrials.gov record NCT06792695. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)
Study identification
- NCT ID
- NCT06792695
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) Drug
- Volrustomig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2025
- Primary completion
- May 30, 2027
- Completion
- Jun 6, 2028
- Last update posted
- Apr 19, 2026
2025 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | Recruiting |
| Research Site | Los Angeles | California | 90089 | Recruiting |
| Research Site | Washington D.C. | District of Columbia | 20007 | Not yet recruiting |
| Research Site | Chicago | Illinois | 60637 | Not yet recruiting |
| Research Site | Baltimore | Maryland | 21224 | Recruiting |
| Research Site | Boston | Massachusetts | 02114 | Completed |
| Research Site | Rochester | Minnesota | 55905 | Recruiting |
| Research Site | Trenton | New Jersey | 08690 | Not yet recruiting |
| Research Site | Rochester | New York | 14618 | Recruiting |
| Research Site | Cleveland | Ohio | 44106 | Withdrawn |
| Research Site | Portland | Oregon | 97239 | Not yet recruiting |
| Research Site | Philadelphia | Pennsylvania | 19104 | Withdrawn |
| Research Site | Nashville | Tennessee | 37232 | Not yet recruiting |
| Research Site | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06792695, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2026 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06792695 live on ClinicalTrials.gov.